AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study - Zacks.com

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study  Zacks.com

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.



Comments

Popular posts from this blog